Prothrombin Complex Concentrates Market, by Type (3-FactorPCC and 4-Factor PCC), by Application (Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, and Others), by End User (Hospital, Ambulatory Surgical Centres and Others),

Prothrombin Complex Concentrates Market, by Type (3-FactorPCC and 4-Factor PCC), by Application (Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, and Others), by End User (Hospital, Ambulatory Surgical Centres and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Prothrombin complex concentrates (PCCs) are highly purified concentrate prepared from blood plasma with hemostatic activity contain four vitamin K-dependent clotting factors (F) (II (prothrombin), VII, IX and X), for replacement therapy in patients with congenital or acquired deficiencies.
Moreover, in several European countries, prothrombin complex concentrates are also used in the management of massive peri- and postoperative bleeding.
Market Dynamics
Global Prothrombin Complex Concentrates Market is expected to show significant growth, owing to increasing approval of product. For instance, in 2013, the U.S Food and Drug Administration (FDA) accepted Octapharma USA’s Biological License Application (BLA) for octaplex 4-Factor PCC, for indication of reversal of anticoagulation therapy in patients undergoing vitamin K antagonist therapy with the need for urgent surgery or invasive procedures
Key features of the study:
This report provides in-depth analysis of the global prothrombin complex concentrates market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global prothrombin complex concentrates market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Octapharma AG, Nihon Pharmaceutical Co Ltd, Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global prothrombin complex concentrates market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prothrombin complex concentrates market
Detailed Segmentation:
Global Prothrombin Complex Concentrates Market, By Type:
3-Factor PCC
4-Factor PCC
Global Prothrombin Complex Concentrates Market, By Application:
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others
Global Prothrombin Complex Concentrates Market, By End User:
Hospital
Ambulatory Surgical Centres
Others
Global Prothrombin Complex Concentrates Market, By Region:
North America
By Type
3-Factor PCC
4-Factor PCC
By Application
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others
By End User
Hospital
Ambulatory Surgical Centres
Others
By Country
U.S.
Canada
Latin America
By Type
3-Factor PCC
4-Factor PCC
By Application
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others
By End User
Hospital
Ambulatory Surgical Centres
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type
3-Factor PCC
4-Factor PCC
By Application
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others
By End User
Hospital
Ambulatory Surgical Centres
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type
3-Factor PCC
4-Factor PCC
By Application
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others
By End User
Hospital
Ambulatory Surgical Centres
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type
3-Factor PCC
4-Factor PCC
By Application
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others
By End User
Hospital
Ambulatory Surgical Centres
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Type
3-Factor PCC
4-Factor PCC
By Application
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others
By End User
Hospital
Ambulatory Surgical Centres
Others
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Octapharma AG*
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Nihon Pharmaceutical Co Ltd
Grifols S.A.
CSL Behring GmbH
Kedrion Biopharma Inc.
Shire Plc
China Biologic Products Holdings, Inc.
Sanquin
“*” marked represents similar segmentation in other categories in the respective section.